CLB — Core Laboratories Income Statement
0.000.00%
Last trade - 00:00
- $779.82m
- $932.83m
- $509.79m
- 98
- 34
- 24
- 51
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 668 | 487 | 470 | 490 | 510 |
Cost of Revenue | |||||
Gross Profit | 173 | 113 | 102 | 96.1 | 110 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 572 | 564 | 425 | 448 | 455 |
Operating Profit | 96.7 | -76.8 | 45.3 | 41.5 | 54.6 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | 82 | -91.2 | 36.1 | 30 | 41.2 |
Provision for Income Taxes | |||||
Net Income After Taxes | 94.3 | -97.1 | 20.2 | 19.7 | 37 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 102 | -97.6 | 19.7 | 19.5 | 36.7 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 102 | -97.6 | 19.7 | 19.5 | 36.7 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 2.08 | -0.209 | 0.405 | 0.447 | 0.82 |
Dividends per Share |